MATTR
18.6.2021 07:02:10 CEST | Business Wire | Press release
MATTR, a provider of verifiable data and digital trust solutions, today announced the availability of the MATTR VII platform on Auth0 Marketplace , a catalog of trusted technology integrations to extend the functionality of Auth0’s identity management platform.
The MATTR VII platform provides an integrated approach to decentralised identity and data ownership. It decouples a user’s identity from their service providers, delivering significant benefits to users and giving builders and developers all the tools they need to create a whole new universe of decentralized products and applications. MATTR VII is composable and configurable to fit developers’ needs, whether it’s a well-established business with legacy systems or a start-up looking to build the next best thing in digital privacy.
“MATTR is pleased to partner with Auth0, and welcomes Auth0’s recognition that MATTR’s approach to decentralised identity and data ownership can provide a powerful way to extend and enhance investment already made in authentication and identity solutions,” said Claire Barber, CEO at MATTR. “We’re looking forward to seeing the innovation and value that these new tools are used to create.”
“It has been really exciting to work with MATTR on a newly-built partner integration for the Auth0 Marketplace . This best-in-class solution adds an integral layer to our platform that provides our customers with greater choice and flexibility,” said Cassio Sampaio, SVP of Product at Auth0. “After speaking with many customers, we have identified the types of integrations that matter to them, and we are so thrilled to have MATTR as a vetted and valuable vendor in Auth0 Marketplace.”
With MATTR and Auth0, organizations can act as authoritative issuers of verifiable credentials, leveraging their existing Auth0 accounts and OpenID Connect flows to issue portable credentials to employees, customers or partners.
MATTR VII with the OIDC Bridge Extension complements Auth0 Extensible Identity, and the ease in which customers can seamlessly integrate adjacent technologies to facilitate the successful execution of larger projects such as digital transformation, threat detection, compliance, and customer conversion.
All partner integrations are thoroughly vetted and verified for security and functionality by Auth0, and are easily discoverable for customers. Partners can participate in the growing demand for digital identity solutions and increase their visibility as part of the Auth0 Marketplace, and can learn more here: https://auth0.com/partners .
About Auth0
Auth0’s modern approach to identity enables organizations to provide secure access to any application, for any user. The Auth0 platform is a highly customizable identity operating system that is as simple as development teams want and as flexible as they need. Safeguarding billions of login transactions each month, Auth0 delivers convenience, privacy, and security so customers can focus on innovation. For more information, visit https://auth0.com
.
About MATTR
MATTR is building a web of trust, restoring confidence in digital interactions through an integrated approach to decentralised identity and data ownership. The MATTR VII platform provides the building blocks to address the historically difficult challenges of digital security, privacy and data verification. Our products are simple, accessible and easy to use, with pre-built extensions that make it easy to plug the platform into existing application stacks. MATTR is committed to open standards, and works with organisations such as W3C, DIF and OIDF.
For more information visit https://mattr.global or follow @MattrGlobal on Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005938/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
